JAN 13, 2022 7:00 AM PST

Gene Unveiled as Missing Link in Antibody Development

WRITTEN BY: Tara Fernandez

Antibodies are a core part of the immune system's pathogen-fighting arsenal, defending the body against bacteria, viruses, and other disease-causing agents. Interestingly, despite antibodies' significant life-saving role, aspects of how the antibodies develop and mature have, until now, remained a black box to immunologists.

Recently, a team of Canadian researchers has discovered a gene called FAM72A that they show is a pivotal part of how the body produces high-quality antibodies, adding another missing piece to the complex immunological puzzle. 

FAM72A works in concert with an enzyme called Activation-Induced Deaminase, or AID, to generate (good) mutations in antibody genes. These mutations are crucial to driving the antibody diversity and potency needed to fight off a range of infectious disease agents. 

Their findings were published in the journal Nature.

This new data has important implications not just in expanding our understanding of somatic hypermutation and class-switch recombination (two key processes in antibody development) but may also unlock novel strategies to treat cancer. Breast, ovarian, liver, and other cancers have been found to have exceedingly elevated levels of FAM72A activity. 

"Our data show that high levels of FAM72A promote mutations in antibody genes, so increased levels of FAM72A could spur cancer development, progression or drug resistance by increasing mutagenesis," said Alberto Martin, the immunologist who led the groundbreaking study.

As part of their work, Martin and colleagues also generated a genetically-engineered mouse model where the animals were deficient in FAM72A. They confirmed their hypothesis, demonstrating that these animals had a compromised antibody response to infections.

"By disabling the DNA repair pathways that normally efficiently remove deoxyuracils from DNA, FAM72A enables AID to exert its full effects on antibody maturation," wrote the authors.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
OCT 19, 2021
Drug Discovery & Development
Researchers develop a potent antiviral drug for dengue fever
OCT 19, 2021
Researchers develop a potent antiviral drug for dengue fever
Dengue fever is a mosquito borne illness that is widespread, especially in tropical countries. The global incidence of d ...
NOV 10, 2021
Health & Medicine
Zinc for Respiratory Infections
NOV 10, 2021
Zinc for Respiratory Infections
With zinc sales climbing during the pandemic and in vitro studies showing the mineral fights respiratory viruses, includ ...
NOV 17, 2021
Microbiology
Large Flu Outbreak at the University of Michigan Draws CDC's Attention
NOV 17, 2021
Large Flu Outbreak at the University of Michigan Draws CDC's Attention
Every year, there is a flu outbreak, and the severity can depend on many factors, like what strain is circulating. Last ...
DEC 23, 2021
Immunology
Hitting the Anti-inflammatory Bullseye to Treat IBD
DEC 23, 2021
Hitting the Anti-inflammatory Bullseye to Treat IBD
Fifty percent—that’s the percentage of patients with inflammatory bowel disease (IBD) who experience long-te ...
DEC 30, 2021
Cell & Molecular Biology
Researchers Discover Immune Cell Subtype Linked to MS and Neuroinflammation
DEC 30, 2021
Researchers Discover Immune Cell Subtype Linked to MS and Neuroinflammation
We still don't know exactly what causes multiple sclerosis (MS), or many other disorders that involve inflammation in th ...
JAN 13, 2022
Cancer
An Arthritis Drug Combats Chemoresistance in Pancreatic Cancer
JAN 13, 2022
An Arthritis Drug Combats Chemoresistance in Pancreatic Cancer
The American Cancer Society estimates the lifetime risk of pancreatic cancer at about 1 in 64. Pancreatic duct ...
Loading Comments...